In atherosclerosis, visceral obesity, and pulmonary fibrosis, the beneficial effects have been replicated with administration a monoclonal antibody, which inhibits PAPP-A activity (60‐62). This evidence concerns the gene PAPPA and pulmonary fibrosis.